Interní Med. 2006; 8(5): 235-239

The cystic fibrosis

MUDr. Petr Jakubec
Klinika plicních nemocí a tuberkulózy, FN a LF UP Olomouc

Cystic fibrosis is the most lethal autosomal recessive disease in Caucasians. The most serious pathological changes are situated in airways, lung and pancreas, but cystic fibrosis afflicts other parts of the digestive tract, genital system and skin. Heart is involved rarely too. The most common cause of death are the lung damage and cardiopulmonary failure. The length of life of CF patients was only a few of years in the past. The average survival is about 35 years owing to management advances today. The gene therapy is great hope to the future.

Keywords: Key words: cystic fibrosis, CFTR gene, diagnostics, management.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jakubec P. The cystic fibrosis. Interní Med. 2006;8(5):235-239.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 2004; 23: 146-158. Go to original source... Go to PubMed...
    2. Brennan AL, Geddes DM, Gyi KM, Baker, EH. Clinical importace of cystic fibrosis-related diabetes. Journal of Cystic Fibrosis 2004; 3 (4): 209-222. Go to original source... Go to PubMed...
    3. Chernish RN, Shawn DA. Approach to Resistant Gram-Negative Bacterial Pulmonary Infections in Patients With Cystic Fibrosis. Curr.Opin.Pulm.Med. 2003; 9 (6): 509-515. Go to original source... Go to PubMed...
    4. Colombo C, Battezzati PM, Crosignani A, et al. Liver Disease in Cystic Fibrosis: A Prospective Study on Incidence, Risk Factors, and Outcome. Hematology 2002; 36: 1374-1382. Go to original source...
    5. Courtney JM, Dunbar KEA, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. Journal of Cystic Fibrosis 2004; 3 (2): 93-98. Go to original source... Go to PubMed...
    6. Courtney JM, Ennis M, Elborn JS. Cytokines and inflammatory mediators in cystic fibrosis. Journal of Cystic Fibrosis 2004; 3 (4): 223-232. Go to original source... Go to PubMed...
    7. Döring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European konsensus. Eur. Respir. J. 2000; 16: 749-767. Go to original source... Go to PubMed...
    8. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst. Rev. 2005 Apr. 18, (2): CD002007. Go to original source... Go to PubMed...
    9. Fila L, Musil J, Vávrová V, Prusík F. Stenotrophomonas maltophilia u nemocných s cystickou fibrózou. Stud. Pneum. Phtis. 2005; 65, 4: 160-165.
    10. Koelling TM, Dec GW, Ginns LC, Semigran MJ. Left Ventricular Diastolic Function in Patients With Advances Cystic Fibrosis. Chest 2003; 123: 1488-1494. Go to original source... Go to PubMed...
    11. Macintosh I, Cutting GR. Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis. FASEB J. 1992; 6: 2775-2782. Go to original source... Go to PubMed...
    12. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective kohort study. Lancet 2003; 361, 9370: 1671-1676. Go to original source... Go to PubMed...
    13. Prescott WA, Johnson CE. Antiinflammatory Therapies for Cystic Fibrosis: Past, Present, and Future. Pharmacotherapy 2005; 25 (4): 555-573. Go to original source... Go to PubMed...
    14. Rowntree RK, Harris A. The Phenotypic Consequences of CFTR Mutations. Annals of Human Genetics 2003, 67: 471-485. Go to original source... Go to PubMed...
    15. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European Concensus. Journal of Cystic Fibrosis 2002; 1: 51-75. Go to original source... Go to PubMed...
    16. Slieker MG, Sanders EAM, Rijkers GT, et al. Disease modifying genes in cystic fibrosis. Journal of Cystic Fibrosis 2005; 4 (2): 7-14. Go to original source... Go to PubMed...
    17. Terheggen-Lagro, SWJ, Rijkers, GT, van der Ent, CK. The role of airway epithelium and blood neutrophils in the inflammatory response in cystic fibrosis. Journal of Cystic Fibrosis 2005; 4 (2): 15-24. Go to original source... Go to PubMed...
    18. Tramper-Stranders, GA, van der Ent, CK, Wolfs, TFW. Detection of Pseudomonas aeruginosa in patients with cystic fibrosis. Journal of Cystic Fibrosis 2005; 4 (2): 37-44. Go to original source... Go to PubMed...
    19. Vávrová V, et al. Cystická fibróza v praxi. 1. vydání Praha, Kreace 1999: 31.
    20. Wood LG, Gibson PG, Garg ML. Circulating markers to assess nutritional therapy in cystic fibrosis. Clinica Chimica Acta 2005; 353, 1-2: 13-29. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.